Anti-tumor Specific Immune Response in Head and Neck Cancers

Anti-tumor Specific Immune Response in Head and Neck Cancers

The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head & Neck Squamous Cell Carcinoma

Secondary purposes are:

• Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs);
• Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS
• Study of relationship between anti-tumor immune response and clinical stage as well as DFS.

Inclusion Criteria:

• Patient with Head & Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy)
• Consent to participate to the study, non-opposition
• Affiliation to social security

Exclusion Criteria:

• History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy
• HIV infection
• Corticotherapy during 15 days before blood sampling